Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Spartalizumab - Novartis Oncology

Drug Profile

Spartalizumab - Novartis Oncology

Alternative Names: PDR 001

Latest Information Update: 02 Jan 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Developer National Taiwan University Hospital; Novartis
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 receptor antagonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Malignant melanoma
  • Phase II Breast cancer; Colorectal cancer; Diffuse large B cell lymphoma; Gastric cancer; Nasopharyngeal cancer; Non-small cell lung cancer; Solid tumours
  • Phase I/II Gastrointestinal stromal tumours; Liver cancer
  • Phase I Acute myeloid leukaemia; Lymphoma; Multiple myeloma; Myelodysplastic syndromes; Ovarian cancer; Renal cancer; Renal cell carcinoma; Squamous cell cancer
  • Discontinued Neuroendocrine tumours

Most Recent Events

  • 01 Jan 2020 Phase-I clinical trials in Squamous cell cancer (Recurrent, Metastatic disease, Second-line therapy or greater) in Taiwan (IV) (NCT04213404)
  • 27 Dec 2019 Sparatalizumab is still in phase I trials for Lymphoma in Canada, United Kingdom, Singapore, USA and Spain (NCT02740270)
  • 11 Dec 2019 Novartis and Emory University plans a phase-Ib/II trial for Pancreatic cancer (Combination therapy, Metastatic disease, Second-line therapy or greater) in USA (IV), (NCT04191421)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top